Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?

Strahlentherapie und Onkologie

Volumn 182, Issue 9, 2006, Pages 543-549

  Sanguineti, Giuseppe ^a   Cavey, Matthew L ^a   Endres, Eugene J ^b   Franzone, Paola ^c   Barra, Salvina ^c   Parker, Brent C ^b   Marcenaro, Michela ^c   Colman, Martin ^a   Agostinelli, Stefano ^c   Foppiano, Franca ^c   Vitale, Vito ^c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

IMRT; Late rectal toxicity; Whole pelvis radiotherapy

Indexed keywords

AGED; ARTICLE; CHRONIC TOXICITY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; PELVIS LYMPH NODE; RADIATION DOSE; RECTUM DISEASE; RECTUM HEMORRHAGE;

ACTUARIAL ANALYSIS; AGED; DATA INTERPRETATION, STATISTICAL; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MALE; PELVIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; TIME FACTORS;

EID: 33748143474     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1586-9     Document Type: Article

References (33)

1. Ashman JB, Zelefsky MJ, Hunt MS, et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:765-71.
2. Bauman G, Rodrigues G. In regard to Fiorino et al.: Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:953-62). Int J Radiat Oncol Biol Phys 2004;59:912-4, author reply 914-5.
3. Bedford JL, Khoo VS, Webb S, et al. Optimization of coplanar six-field techniques for conformal radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 2000;46:231-8.
4. Bieri S, Bentzen SM, Huguenin P, et al. Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer. Experience from four nonrandomized studies. Strahlenther Onkol 2003;179:390-5.
5. Cavey ML, Bayouth JE, Colman M, et al. IMRT to escalate the dose to the prostate while treating the pelvic nodes. Strahlenther Onkol 2005;181:431-41.
6. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
7. Feigenberg SJ, Hanlon AL, Horwitz EM, et al. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2005;62:397-405.
8. Fiorino C, Cozzarini C, Vavassori V, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 2002;64:1-12.
9. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;57:953-62.
10. Gershkevitsh E, Clark CH, Staffurth J, et al. Dose to bone marrow using IMRT techniques in prostate cancer patients. Strahlenther Onkol 2005;181:172-8.
11. Jacob R, Hanlon AL, Horwitz EM, et al. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 2005;61:695-701.
12. Khoo VS, Bedford JL, Webb S, et al. An evaluation of three-field coplanar plans for conformal radiotherapy of prostate cancer. Radiother Oncol 2000;55:31-40.
13. Khoo VS, Bedford JL, Webb S, et al. Evaluation of the optimal co-planar field arrangement for use in the boost phase of dose escalated conformal radiotherapy for localized prostate cancer. Br J Radiol 2001;74:177-82.
14. Koelbl O, Schwab F, Bratengeier K, et al. Radiotherapy of prostate cancer with multileaf collimators (MLCs) optimization of the undulating dose distribution at the MLC edge. Strahlenther Onkol 2005;181:108-12.
15. Lawton CA, DeSilvio M, Roach M, et al. An update of the phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): updated analysis of RTOG 9413. Int J Radiat Oncol Biol Phys 2005;63:S19.abstract.
16. Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2004;59:267-84.
17. Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:649-56.
18. O'Brien PC, Hamilton CS, Denham JW, et al. Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:75-80.
19. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34.
20. Perez CA, Lee HK, Georgiou A, et al. Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994;28:811-9.
21. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 1996;77:834-42.
22. Pickett B, Roach M 3rd, Horine P, et al. Optimization of the oblique angles in the treatment of prostate cancer during six-field conformal radiotherapy. Med Dosim 1994;19:237-54.
23. Radiation Therapy Oncology Group. A phase III randomized study of high dose 3D-CRT versus standard dose 3D-CRT in patients treated for localized prostate cancer. Protocol P0126 (www.rtog.org).
24. Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21:1904-11.
25. Rosen E, Cassady JR, Connolly J, et al. Radiotherapy for prostate carcinoma: the JCRT experience (1968-1978). II. Factors related to tumor control and complications. Int J Radiat Oncol Biol Phys 1985;11:723-30.
26. Sanguineti G, Agostinelli S, Foppiano F, et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer 2002;86:1843-7.
27. Sanguineti G, Castellone P, Foppiano F, et al. Anatomic variations due to radical prostatectomy. Impact on target volume definition and dose-volume parameters of rectum and bladder. Strahlenther Onkol 2004;180:563-72.
28. Sanguineti G, Cavey ML, Endres EJ, et al. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer? Int J Radiat Oncol Biol Phys 2005;64:151-160.
29. Sanguineti G, Culp L, Pena J, et al. Acute small bowel and colon toxicity after pelvic IMRT for prostate cancer. Eur J Cancer Suppl 2003;1:S268. abstract.
30. Teshima T, Hanks GE, Hanlon AL, et al. Rectal bleeding after conformal 3D treatment of prostate cancer: time to occurrence, response to treatment and duration of morbidity. Int J Radiat Oncol Biol Phys 1997;39:77-83.
31. Villeirs GM, Van Vaerenbergh K, Vakaet L, et al. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol 2005;181:424-30.
32. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-6.
33. Zelefsky MJ, Moughan J, Owen J, et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 patterns of care survey for prostate cancer. Int J Radiat Oncol Biol Phys 2004;59:1053-61.